Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.
about
The Role of Interleukin-17 in Lung CancermiR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA)A laboratory prognostic index model for patients with advanced non-small cell lung cancerPretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis.Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests.Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancerA new inflammation index is useful for patients with esophageal squamous cell carcinoma.Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: a microarray study.Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patientsPrognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients.Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis.Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysisPreoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer.Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases.Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung CancerCachexia Index in Advanced Non-Small-Cell Lung Cancer Patients.Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.Neutrophil-to-lymphocyte ratio is effective prognostic indicator for post-amputation patients with critical limb ischemia.Application of clinical bioinformatics in lung cancer-specific biomarkers.Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer CasesPhase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients.Decision support systems for incurable non-small cell lung cancer: a systematic reviewAnti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.Contrast-enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early-phase non-small cell lung cancer.An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.Combination of Advanced Lung Cancer Inflammation Index and C-Reactive Protein Is a Prognostic Factor in Patients With Operable Non-Small Cell Lung Cancer.Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy.The advanced lung cancer inflammation index is an independent prognostic factor after surgical resection in patients with non-small-cell lung cancer.Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
P2860
Q28066949-7D34D2A5-B3B9-4488-8CC3-29FD449A47C7Q28394161-235263BC-57AE-4565-8C23-AD0BAFD82C30Q28542513-C1B4E479-06D4-4293-B99C-4A20A8CB8BECQ30235263-2F511093-CA0D-4CDC-80C0-3D12D9EABEC8Q30827122-0C3B3348-A799-43AD-AE8F-1F3E9F5BB74BQ33816141-2A4323D7-0060-4A22-AE6F-E7C3F3D27415Q34215504-FF54678B-4F79-4E12-B4C1-9C0346B68D7CQ34352751-355EF47D-8AEA-4546-B9A1-406787747658Q34733257-FABDD891-30FB-444B-86FC-D44A56CC7A2AQ35663441-6DC76D7F-21D7-400C-98B2-343DEDB7B4E2Q35817001-DFF8883B-E97B-4B15-B6C0-152DF15FA88EQ35884531-E07A212C-5C61-4C61-B521-D5EEBF07A9D3Q36027639-96D84138-65E1-4245-9F0D-6D030D72478BQ36046192-C8FC5623-5AB8-4927-A46E-55FECA4C593EQ36111909-80709FAF-4533-4C3E-BBE4-EF1DB2A050B2Q36140803-C576F468-CC51-4230-B4BA-38165997A633Q36151154-B9E7961D-D5AF-43D7-A6A1-89F2C4D6B153Q36267710-FEEDF5DD-7C70-4F78-9760-F9E22C95FC36Q36283286-CECA674F-83DA-4DB6-9014-6CA5BC98D0C8Q36560502-4677C075-C582-462A-81A8-81A8A6EA1306Q36821179-1F211AE4-83DC-487B-92D2-04CC510417AAQ37611903-3500991A-E09C-4DBC-A4EB-79E5FBD322B8Q38453827-F8553943-8159-445F-85B4-77B9D0B269FDQ38769899-153E2FEA-9E45-42FA-A223-E94EA60A6545Q38797202-6B94E770-0094-4F95-8D5D-A40235CF5566Q38843604-3778AE45-723B-4F67-80D6-8908C3DB0BC2Q38999324-BC16AD96-6C6B-4649-AF4D-E0C4480165DBQ40153561-8B421A4B-ADD1-494F-BF85-C35CFE6C2864Q40313897-4C0AAA55-D843-45E2-8F14-735CB4E0B00EQ41283854-1B2A6292-A5F4-432D-BB29-A4FAFBFBA327Q41544840-D61F2209-438C-45D1-B46B-84FD29A02188Q42284446-7839B90E-B220-4B86-B280-B0F9DBEB2F35Q47104348-4FE7305B-6626-4367-B194-5037F20D6A68Q47104384-639C9E20-1EF0-4234-96C5-D4145A7CDA01Q47151590-152D4D92-2FAE-4F04-BBA5-3E75076727C1Q47215319-D6B35B5E-29DB-4265-9FEA-AFE1C21B5F82Q47356300-1308F1E8-207F-4331-AF92-39FB8320D515Q47628738-D623D1CF-8DD1-4DB8-ADAF-F6681DC5487BQ48278429-EC1AFED4-2474-4A21-AFDB-11BC3737159CQ50016409-5AA67D2D-9332-4CA5-B505-5C538E1B5008
P2860
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Advance lung cancer inflammati ...... SCLC): a retrospective review.
@ast
Advance lung cancer inflammati ...... SCLC): a retrospective review.
@en
Advance lung cancer inflammation index
@nl
type
label
Advance lung cancer inflammati ...... SCLC): a retrospective review.
@ast
Advance lung cancer inflammati ...... SCLC): a retrospective review.
@en
Advance lung cancer inflammation index
@nl
prefLabel
Advance lung cancer inflammati ...... SCLC): a retrospective review.
@ast
Advance lung cancer inflammati ...... SCLC): a retrospective review.
@en
Advance lung cancer inflammation index
@nl
P2093
P2860
P921
P356
P1433
P1476
Advance lung cancer inflammati ...... SCLC): a retrospective review.
@en
P2093
Glenn Mills
Runhua Shi
Syed H Jafri
P2860
P2888
P356
10.1186/1471-2407-13-158
P407
P5008
P577
2013-03-27T00:00:00Z
P5875
P6179
1014807789